Showing 2241-2250 of 4063 results for "".
- Sandoz Receives FDA Approval for Eylea Biosimilar Enzeevuhttps://modernod.com/news/sandoz-receives-fda-approval-for-eylea-biosimilar-enzeevu/2482396/The FDA has approved Sandoz's Enzeevu (aflibercept-abzv), an Eylea biosimilar, for the treatment of wet age-related macular degeneration (AMD). The approval includes both a 2 mg vial kit and a pre-filled syringe for intravitreal injection. The FDA provisionally
- New Data for Susvimo Demonstrates Sustained Efficacy in DME and DRhttps://modernod.com/news/new-data-for-susvimo-demonstrates-sustained-efficacy-in-dme-and-dr/2482365/Genentech and Roche announced 2-year data from the phase 3 Pagoda and Pavilion studies evaluating Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively. Susvimo, which is being
- Okyo Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101https://modernod.com/news/okyo-pharma-to-initiate-neuropathic-corneal-pain-trial-for-ok-101/2482353/Okyo Pharma announced its plan to advance OK-101 into a phase 2 clinical trial of neuropathic corneal pain which is expected to begin in Q3 2024. This 1-year study is supported by preclinical animal model data and statistically significant pain relief observe
- Beacon Therapeutics Raises Funds to Advance Development of Its Ophthalmic Gene Therapieshttps://modernod.com/news/beacon-therapeutics-raises-funds-to-advance-development-of-its-ophthalmic-gene-therapies/2482341/Beacon Therapeutics announced it has raised $170 million in Series B funding, which will be used to support the continued clinical development of Beacon’s lead asset, AGTC-501, for X-linked retinitis pigmentosa (XLRP; laruparetigene zovaparvovec) and generate phase 1/2 clinical trial d
- Bausch + Lomb Launches Blink NutriTears Nutritional Supplement for Dry Eyes in the UShttps://modernod.com/news/bausch-lomb-launches-blink-nutritears-nutritional-supplement-for-dry-eyes-in-the-us/2482305/Bausch + Lomb announced the US launch of Blink NutriTears, an over-the-counter supplement designed to target the key root causes of dry eyes, promote healthy tear production, and provide relief of eye dryness symptoms in as little as 2 to 4 weeks.[1,2]
- Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in GAhttps://modernod.com/news/annexon-presents-new-neuroprotection-data-showing-anx007-protects-vision-and-vision-associated-structures-in-ga/2482268/Annexon presented new analyses of ANX007 from the phase 2 ARCHER trial in geographic atrophy (GA), and new preclinical data on the role of C1q in the pathogenic elimination of photoreceptor synapses and their protection with C1q blockade in GA. ANX007 is a first-in-class, non-pegylated
- Lenz Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trialshttps://modernod.com/news/lenz-therapeutics-announces-positive-topline-data-from-phase-3-clarity-presbyopia-trials/2482207/Lenz Therapeutics announced positive topline results from its phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia. In phase 3 safety and efficacy trials (CLARITY 1 and 2), our lead product candidate LNZ100 (1.75% ac
- Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseaseshttps://modernod.com/news/azura-ophthalmics-to-present-new-data-supporting-the-potential-of-azr-md-001-to-be-the-first-ophthalmic-keratolytic-for-ocular-surface-diseases/2482185/Azura Ophthalmics announced multiple presentations highlighting positive efficacy and safety data from phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in meibomian gland dysfunction (MGD). This includes new, long-term data at ASCRS of the company’s lead drug candidat
- Ocuphire Pharma Receives FDA Agreement for Phase 3 Trial of Phentolamine Solution for Poor Night Visionhttps://modernod.com/news/ocuphire-pharma-receives-fda-agreement-for-phase-3-trial-of-phentolamine-solution-for-the-treatment-of-decreased-visual-acuity-under-dim-light-conditions/2482041/Ocuphire Pharma announced it has received agreement from the FDA under a special protocol assessment (SPA) for the clinical trial protocol and planned statistical analysis of the LYNX-2 phase 3 trial to evaluate phentolamine ophthalmic solution for the proposed indication for the treatm
- Aetna Rolls Back Prior Authorization for Cataract Surgeries for Medicare Advantage Beneficiaries in Georgiahttps://modernod.com/news/aetna-rolls-back-prior-authorization-for-cataract-surgeries-for-medicare-advantage-beneficiaries-in-georgia-1/2482030/After 2 years of advocacy from the ophthalmology community, Aetna confirmed in a letter to the American Academy of Ophthalmology that it will no longer require preapproval for cataract surgeries for Medicare Advantage beneficiaries in Georgia, starting Jan.1. Last year, the insurer rolled back th